ERYTECH's Lead AML Drug Flunks Phase II Test Post author:Sam Post published:December 7, 2017 Post category:BioPharma The study enrolled a total of 123 patients at 30 European sites. Source: BioSpace You Might Also Like Adaptimmune Announces Closing Of $42 Million Registered Direct Offering April 10, 2017 Alexion Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint and Arbutus Biopharma July 26, 2017 Japanese Pharma Giant Astellas Sets Up Shop in Cambridge July 24, 2017
Alexion Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint and Arbutus Biopharma July 26, 2017
